Epidermal growth factor inhibits phosphoenolpyruvate carboxykinase gene expression in rat hepatocytes in primary culture  by Fillat, Cristina et al.
Volume 318, number 3, 287-291 FEBS 12174 
0 1993 Federation at” European Biochemtcal Societies 00145793/93/$6.00 
March 1993 
Epidermal growth factor inhibits ~~os~hu~~ul~y~uvat~ carboxykinase 
gene expression in rat hepatocytes in primary culture 
Cristina Fillat, Alfons Valera and Fatima Bosch 
Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Autonomous University of Barcelona, 
~~~9~-~e~~ateY~a, ~ rce~o~a, Spain 
Received 13 January $993 
Epidertnal growth factor (EGF) decreased the basal, and blocked the dibutyryi cyclic AMP (Bt,cAMP)-induced, expression of P-enolpyruvate 
carboxykinase (GTP) (PEPCK) and tyrosine aminotransferase (TAT) genes m both rat hepatocytes m primary culture and the FTO-2B hepatoma 
cell line. Treatment of hepatocytes with EGF in combination with phorbol ester (TPA) resulted m an additive decrease of PEPCK mRNA levels. 
Overnight pretreatment af hepatocytes with TPA, which is known to downregulate protein kinase C, abolished the TPA and reduced 
the EGF-mediated inhibition of PEPCK gene expresaon. These results suggested that EGF caused its effect, at least in part, through protein 
kinase C. 
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1. INTRODUCTION 
Epidermal growth factor (EGF) is a polypeptide that 
increases kin growth of newborn mice and may also act 
as a mitogen in a variety of cell types [1,2], EGF, like 
insulin, has a receptor that exhibits tyrosine kinase ac- 
tivity f3f. Liver membranes and isolated hepatocytes 
bind EGF specifically. Both the EGF-receptor number 
and tyrosine kinase activity decrease during starvation 
in the rat liver [4], suggesting that EGF may have a 
physiological role in the liver. EGF has a profound 
effect in different cellular processes including alteration 
of gene expression. It has been reported that EGF in- 
creased the levels of c-fis mRNA in 3T3 cells IS], in 
H4IIE hepatoma [6], and in A431 epidermoid carci- 
noma [7) cells. In A431 cells. EGF also induced c-myc 
mRNA production [7]. In addition, it has been shown 
that EGF modifies the carbohydrate metabolism in dif- 
ferent cell types [s-la]. The intracellular signals in- 
volved in EGF action are not well understood. How- 
ever, a mechanism for the effwt of EGF in these diverse 
processes has been linked to the activation of the phos- 
pholipase C-r (PLC-r) as a result ofphospho~iation on 
tyrosine residues by EGF receptor tyrosine kinase 
[ 11,121. The activation of PLC-r enhances the break- 
down of phosphatidilinositol4,5-bisphosphate in a va- 
riety of cell types to yield two putative second messen- 
gers: 1,2-dia~yl~~ycerol and myo-inositol 1,4,5-tri- 
phosphate (IPJ [13]. ~ia~ylgly~erol has been shown to 
specifically activate protein kinase C in a calcium-de- 
pendent manner [14], whereas IP, mediates the release 
of free Ca*’ from specific intracellular pools [15]. EGF 
effects mediated by both protein kinase C activation 
[16, f7’1 and alcium mobilization [18] have already been 
described. However, other factors, like neural growth 
factor (NGF) or basic fibroblast growth factor (FGF), 
also stimulate phosphorylation of PLC-z in tyrosine 
1191, and, although many growth factors elicit similar 
early responses, the long-term phenotypic responses to 
these diverse ligands vary. In this regard, NGF and 
basic FGF cause differentiation of PC12 cells, whereas 
EGF is mitogenic [ZOJ. 
Liver glycotysis is induced by insulin @I], EGF fl7], 
vanadate [22] and phorbol ester (TPA) [173, while glu- 
coneogenesis i  blocked 123-251. The cytosolic form of 
P-enolpyruvate carboxykinase (PEPCK) governs the 
rate-limiting step in gluconeogenesis. The activity of the 
enzyme is mainly regulated by changes in the transcrip- 
tion of its gene. Insulin, TPA and vanadate decrease the 
PEPCK gene transcription whereas glu~o~orticoids and 
cAMP have the opposite effect [2632]_ 
The aim of this work was to study whether EGF 
could inhibit PEPCK gene expression either in 
hepatoma cells and hepatocytes in primary culture, and 
whether this effect could be related to an activation of 
protein kinase C. 
2. MATERIALS AND METHODS 
2.1. Narerials 
Correspundeme ad&m: F. Bosch, Department of Biochemistry and The random primer labeling kit, ah restriction enzymes and 
Molecular Biology, School of Veterinary Medicine, Autonomous Uni- &CAMP were obtained from Boehringer Mannheim. [&‘P]dCTP 
versity of Barcelona, 08193-Bellaterra, Barcelona, Spain. Fax: (34) (3) (3.000 Ci/mmol) came from Amersham Corp. GeneScreen Plus was 
581 2006. purchased from DuPont-New England Nuclear. All media and sera 
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were obtained from Gibco Laboratories. EGF and TPA were obtained 
from Sigma. The other reagents used were of the best grade commer- 
cially available. The P-enolpyruvate carboxykinase cDNA was pro- 
vided by Dr. Richard W. Hanson, Case Western University, Cleve- 
land, Ohio, USA. The tyrosine aminotransferase cDNA was a gift 
from Dr. Giinter Schutz, Institut fiir Zell und Tumorbiologie, Hei- 
delberg, Germany. Animal studies were conducted in accord with the 
‘Guidelines for Care and Use of Experimental Animals’. 
2.2. Preparation and incubation of hepatocytes 
Male Sprague-Dawley rats, weighing 200-250 g and fed ad libitum, 
were used in all studies. Hepatocytes were isolated as previously de- 
scribed [33]. After removing nonparenchymal cells and debris, hepato- 
cytes were resuspended in Dulbecco’s minimal essential medium 
(DMEM)containing 0.2% albumin and 10% fetal calf serum. 5.5 x lo6 
cells were plated in 10 mf of this medium on collagen-coated ishes 
and maintained at 37°C under a CO, atmosphere. After 4 h, the 
medium was removed and replaced by 10 ml of fresh DMEM medium 
containing 0.2% albumin without fetal calf serum. Then, one half of 
the cells were pretreated for 16 h with 1 PM TPA. Afterwards, cells 
were incubated with either 0.5 mM Bt,cAMP, 50 nM insulin, 1 PM 
TPA, 33 nM EGF, or with different combinations of the effecters. 
2.3. Northern analysis 
Total RNA was extracted from confluent FTOZB cultures and 
primary hepatocytes by the guanidine isothi~yanate method [34], and 
the RNA samples (20 pug) were electrophoresed on a 1% agarose gel 
containing 2.2 M fo~aldehyde. Northern blots were hybridized to 
3’P-labeled cDNAs. The PEPCK cDNA probe corresponded to a 1.1 
kb PstI-PstI fragment from the 3’ end of the PEPCK cDNA [35]; 
tyrosine aminotransferase cDNA corresponded to a 600-base pair 
PstI-PstI fragment which included the 3’ end of the tyrosine ami- 
notransferase cDNA [36]: the /3-actin probe corresponded to a 1.3 kb 
EcoRI-EcoRI fragment of /I-actin cDNA [37]. Hybridization and 
washing conditions have been described previously [24]. The mem- 
branes were exposed to Kodak XAR-5 film, and densitometric analy- 
sis of autoradiograms was performed at non-saturating exposures 
with a scanning densitometer. The actin signal was used to correct for 
loading inequalities, because the actin RNA levels were not apprecta- 
bly changed by the various treatments. 
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Fig. 1. Effects of EGF on PEPCK and TAT mRNA levels in rat 
hepatocytes in primary culture. Hepatocytes in primary culture were 
treated for 4 h with medium (no hormones added) (Con), with 50 nM 
insulin (Ins) of 33 nM EGF (EGF). RNA was extracted, electropho- 
resed (20 &sample) and probed for PEPCK (panel A) and TAT (B) 
as described in section 2. Signal intensity was quantitated by densitom- 
etry, and the readings obtained in experimental cultures were ex- 
pressed as a percentage of readings in paired control cultures after 
correction for loading inequalities with the /3-actin signal. Each bar 
represents the mean -+ S.E.M. of the observations made in five inde- 
pendent experiments. 
2.4. Presentation of the data and statistical analysis 
In studies of individual RNA samples the correlation coefficient 
between increasing amounts of input RNA and signal intensity was 
0.99 for all three transcripts. To analyze the effects of perturbations 
independently of variability in basal gene expression, the densitomet- 
ric readings of experimental samples were expressed as a percentage 
of readings in paired control samples (always tested in the same North- 
ern blot) after correction for loading differences with the actin signal. 
The data are expressed as the mean f 1 S.E.M. Statistical analysis was 
by the Wilcoxon signed-rank test. 
PEPCK 
Fig. 2. Effects of EGF on PEPCK mRNA levels in FTO-2B rat hepatoma cells. FTO-2B cells were treated with 0.5 mM B&CAMP and 1 mM 
theophylline, 33 nM EGF, 50 nM insulin or with combinations of these effecters for 4 h. Experimental procedures were described in the legend 
to Fig. 1. Each bar represents the mean + S.E.M. of the observations made in three independent experiments. A representative Northern blot is 
presented. 
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3. RESULTS AND DISCUSSION 
3.1. Effects of EGF on PEPCK and TAT gene expres- 
sion 
The effect of EGF on the regulation of PEPCK gene 
expression has been studied using rat hepatocytes in 
primary culture and FTO-2B rat hepatoma cells. Treat- 
ment of hepatocytes for 4 h with EGF caused a strong 
reduction on the PEPCK mRNA basal concentration, 
which decreased to 28 f 10% of control (P < 0.01) (Fig. 
1 A), while no significant inhibitory effect of EGF on the 
basal expression of PEPCK was detected in FTO-2B 
cells (98 ? 14% of control) (Fig. 2A). However, in these 
cells a 50% inhibition of basal PEPCK mRNA levels 
was observed when EGF and insulin were added to- 
gether into the incubation media (48 f 13% of control, 
P < 0.01) while insulin alone only caused a 30% reduc- 
tion (Fig. 2A). As expected, incubation of both hepato- 
cytes and FTO-2B cells with B&AMP increased the 
levels of PEPCK mRNA. EGF blocked this induction 
both in hepatocytes in primary culture and FTO-2B 
hepatoma cells (Figs. 3A and 2B). In hepatocytes, EGF, 
like insulin, caused a 40% inhibition of the Bt,cAMP 
induction of the PEPCK mRNA concentrations (from 
1,360 f 155% to 795 f 106, P < O.Ol), while the block- 
ade was stronger in hepatoma cells, where EGF pro- 
duced a 75% reduction of the CAMP induction of 
PEPCK mRNA levels. 
Since tyrosine aminotransferase (TAT) is also in- 
volved in gluconeogenesis and the expression of its gene 
is regulated in a similar manner to the PEPCK gene 
[38-40], we have studied, in rat hepatocytes in primary 
culture, the effects of EGF on the basal TAT gene ex- 
pression, in comparison to the effects of insulin. EGF 
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Fig. 3. Effects of EGF on CAMP induction of PEPCK and TAT mRNA levels in rat hepatocytes in primary culture. Hepatocytes in primary culture 
were treated for 4 h with 0.5 mM Bt2cAMP, and in combination of 50 nM insulin or 33 nM EGF. Experimental procedures and presentation of 
data are as described in the legend to Fig. 1. Results represent he mean f S.E.M. of five different experiments. A representative Northern blot 
is presented. 
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Fig. 4. Effects of combinations of EGF and TPA on PEPCK mRNA levels. Hepatocytes were treated for 4 h with combinations of 0.5 mM 
Bt,cAMP, 33 nM EGF and/or 1 PM TPA (open bars). In addition (striped bars), cells were pretreated for 16 h with 1 ,uM TPA and then treated 
for 4 additional hours with combinations of 0.5 mM Bt,cAMP, 33 nM EGF and/or I PM TPA. Experimental procedures were described in the 
legend to Fig. 1. Data are expressed as a percentage of CAMP induction. Results represent he mean + S.E.M. of six independent experiments. 
A representative Northern blot IS presented. 
inhibited the TAT mRNA basal levels, with a decrease 
to 42 + 12% of control (P < 0.01) (Fig. lB), while insu- 
lin only reduced the TAT gene expression to 60 + 14% 
of control (Fig. 1B). Treatment of hepatocytes with 
Bt+AMP induced the TAT gene expression. Induction 
was similarly reduced when these hepatocytes were in- 
cubated with either EGF or insulin (Fig. 3B). 
3.2. Effects of combinations of EGF and TPA on 
PEPCK gene expression 
In order to study the mechanism by which EGF in- 
hibited the B&CAMP induction of PEPCK gene expres- 
sion, hepatocytes were treated with EGF, TPA and 
combinations of both effecters. As previously shown in 
hepatoma cells [25], TPA was able to decrease PEPCK 
mRNA levels induced by Bt,cAMP in rat hepatocytes 
in primary culture (Fig. 4). When added together, EGF 
and TPA exerted a more pronounced inhibitor effect 
on PEPCK mRNA levels, which decreased to 35 2 10% 
of CAMP-induced control (P < 0.01). than EGF or TPA 
added alone (Fig. 4). It has been described that phorbol 
esters activate protein kinase C and may stimulate var- 
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ious intracellular events that are mediated through this 
kinase. In order to determine if protein kinase C was 
involved in the EGF effect on PEPCK gene expression, 
hepatocytes were pretreated overnight with 1 ,uM TPA. 
Under these conditions, in which protein kinase C is 
down-regulated [41] a 20% reduction of EGF inhibition 
of Bt,cAMP induction on PEPCK gene expression was 
observed (from 56 f 13% of CAMP-induced control in 
non-pretreated hepatocytes to 76 + 15% in treated 
hepatocytes, P c 0.01). In these conditions, EGF was 
clearly less effective in decreasing PEPCK mRNA levels 
but still had a significant effect (Fig. 4). In TPA pre- 
treated hepatocytes, the addition of both TPA and EGF 
caused an inhibitory effect on Bt,cAMP induced 
PEPCK gene expression (72 + 14%) similar to that ob- 
served when EGF was added alone, while the addition 
of TPA in the pretreated hepatocytes did not produce 
a significant reduction on CAMP-induced PEPCK 
mRNA levels (94 * 20% of CAMP-induced control) 
(Fig. 4). These results suggest hat EGF could act on the 
expression of the PEPCK gene through, at least, two 
different mechanisms, one dependent and another inde- 
pendent of protein kinase C. 
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